CAGRILINTIDE

Chemical Makeup:

• Molecular Formula: C194, H312, N54, O59, S2
• Molecular Weight: 4409.1 g/mol
• Synonyms: AM833, NN0174-0833, Cagrilintide Acetate, Long-Acting Amylin Analogue

Sequence:

Ac-Lys(1)-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2 (Bridge: 2-7)

[CAGRILINTIDE] and Appetite Regulation

Research in murine models suggests that Cagrilintide influences the central regulation of appetite through the activation of AMY1, AMY2, and AMY3 receptor subtypes. Studies indicate that administration of the peptide correlates with a reduction in food intake by enhancing satiety signals processed in the brainstem. In comparative studies with native amylin, Cagrilintide exhibited a prolonged duration of action, attributed to its specific fatty acid acylation which promotes albumin binding and reduces renal clearance. It has been observed that the peptide may dampen the "reward" signaling associated with palatable food consumption in rodent models.

[CAGRILINTIDE] and Gastric Motility

One of the distinct physiological effects observed in Cagrilintide research is the modulation of gastric emptying rates. The peptide appears to slow the transit of gastric contents into the small intestine, a mechanism known as the "amylin effect." In clinical assays involving subjects with obesity, this delay in gastric emptying was associated with blunted postprandial glucose excursions. Investigators note that this mechanism is separate from, yet complementary to, the incretin-mediated effects of GLP-1 receptor agonists, suggesting a potential synergistic utility in co-administration protocols.

[CAGRILINTIDE] and Glucose Homeostasis

Studies indicate that Cagrilintide may play a regulatory role in glucagon secretion. In diabetic rat models, the peptide was observed to suppress the inappropriate elevation of glucagon typically seen in the postprandial state. This suppression, combined with the delay in gastric emptying, contributes to a reduction in endogenous glucose production. Furthermore, research suggests that unlike insulin, Cagrilintide does not promote hypoglycemia when administered alone; rather, it modulates the rate of glucose appearance in the circulation.

[CAGRILINTIDE] and Adipose Tissue Metabolism

In pre-clinical trials involving diet-induced obese (DIO) mice, Cagrilintide administration was linked to significant reductions in body weight, primarily driven by a loss of fat mass rather than lean tissue. Research into the specific metabolic pathways suggests that the dual activation of calcitonin receptors may enhance lipolysis or alter energy expenditure profiles. Comparative data indicates that the weight-reducing potential of Cagrilintide in isolation is dose-dependent and distinct from the mechanisms utilized by incretin mimetics.

[CAGRILINTIDE] and Synergistic Interactions (CagriSema)

Current academic interest is heavily focused on the co-administration of Cagrilintide with Semaglutide. Murine studies indicate that the combination of these two peptides engages non-overlapping neural populations in the hypothalamus and hindbrain. It was observed that the simultaneous activation of GLP-1 and amylin/calcitonin receptors resulted in greater weight loss efficacy than either agent used as a monotherapy. This "additive" effect is currently a primary subject of investigation in metabolic research.

If you're not 100% satisfied within the first 30 days, just send it back to us and we'll give you a full refund.

No need to worry about the return shipping - we've got you covered!

We offer fast and reliable shipping on all orders. You can expect to receive it within 7-12 business days based on your location.

Please contact our customer service team for assistance if you have any questions or concerns about your shipment.

Side Effects: 

In animal toxicology studies and early-phase clinical research, the most frequently observed adverse events associated with Cagrilintide were gastrointestinal in nature. Nausea and vomiting were reported in dose-escalation studies involving rats and non-human primates. These effects were noted to be transient and often diminished with continued administration. Reduced appetite and potential withdrawal-induced rebound hyperphagia have been theorized but require further longitudinal study.

Research Use Only: 

This product is intended exclusively for laboratory research and development purposes. It is not intended for human consumption, diagnostic use, or therapeutic procedures. The information provided above is for educational and referencing purposes only and is based on academic literature.